JÖRG MÖLLER

Actio Biosciences

SAMUEL COLLINS

Actio Biosciences has appointed Samuel Collins as chief medical officer. Collins brings nearly two decades of experience spanning academia and industry. He most recently served as vice president, clinical development at Edgewise Therapeutics. Prior to this, he served as senior director, rare disease clinical research at Pfizer, which followed his position as director, rare disease clinical research at the company.

SpliceBio

ANIZ GIRACH

SpliceBio has appointed Aniz Girach as chief medical officer. Girach holds over two decades of industry experience in medical retina and gene therapy for inherited retinal diseases. Most recently, he served as global head, ophthalmology at Merck & Co and vice president, clinical development at Alcon Laboratories. Prior to this, Girach served as global head of ophthalmology and chief medical officer at Oxurion.

Alkeus Pharmaceuticals

SEEMI KHAN

Alkeus Pharmaceuticals has appointed Seemi Khan as chief medical officer. Khan brings nearly two decades of in-depth global research and development experience to her new position. She most recently served as senior vice president and chief medical officer at Reata Pharmaceuticals. Prior to this, Khan held the position of development team lead at Mitsubishi Tanabe Pharma America.

CatalYm

ROY HERBST

CatalYm has appointed Roy Herbst to its scientific advisory board. Herbst has over four decades of experience. He currently serves as ensign professor of medicine, chief of medical oncology, deputy director and associate director of translational research at the Yale Cancer Center. He was also the Barnhart distinguished professor and chief, section of thoracic medical oncology, University of Texas MD Anderson Cancer Center.

CatalYm

ROY BAYNES

CatalYm has appointed Roy Baynes to its board of directors. Baynes has over two decades of pharmaceutical experience and currently serves as executive vice president and chief medical officer at Eikon Therapeutics. Prior to this, Baynes held the position of senior vice president, head of clinical development and chief medical officer at Merck. He also held senior positions at Amgen and Gilead Sciences.

BeiGene

OLIVIER BRANDICOURT

BeiGene has appointed Olivier Brandicourt to its board of directors. Brandicourt has a wealth of experience in management, medical and marketing. He currently serves as senior advisor at Blackstone Life Sciences and director of Alnylam Pharmaceuticals, BenevolentAI and Dewpoint Therapeutics. Brandicourt also serves as chair of the board of AvenCell Therapeutics. Prior to this, he served as chief executive officer at Sanofi.

Revagenix

BRUCE MONTGOMERY

Revagenix has appointed Bruce Montgomery to its board of directors. Montgomery brings over three decades of experience in senior positions to his new role. He currently serves as chief executive officer at WBX Pharma. Prior to this, he served as chief executive officer at Avalyn Pharma, Cardeas Pharma and Corus Pharma. Montgomery also served as senior vice president at Gilead Sciences.

Akiram Therapeutics

PEDER WALBERG

Akiram Therapeutics has appointed Peder Walberg to its board of directors. Walberg brings over two decades of extensive experience in the pharmaceutical industry to his new position. In addition, he currently serves on the board ofdirectors for Egetis Therapeutics and Immedica Pharma. Prior to this, he served as founder and chief executive officer for Rare Thyroid Therapeutics.